‘Win-Win-Win’ MDUFA Letter Wraps Up What Regulatory Expert Calls Smoothest Negotiations Ever
Speed, predictability, and investment in emerging technologies are the hallmarks of the proposed MDUFA VI commitment letter, which stakeholders describe as the product of the smoothest round of negotiations in memory. FDA will hold a public meeting on Aug. 5 before finalizing the agreement.
Medtech Insight - July 23, 2026

VB Spine Acquires Second Augmedics Technology In Push To Undercut Navigation Rivals
VB Spine says its CT-Fluoro technology cuts navigation, needs no separate 3D imaging device, and fits a smaller OR footprint — however, no supporting data has been published and the deal is yet to close.
Medtech Insight - July 23, 2026

EU Okays AstraZeneca’s Etcamah As US Wait Continues
Approval for the breast cancer drug across the Atlantic is some way off. The UK major will be hoping for positive reimbursement talks in Europe so the oral SERD can start contributing to its coffers.
Scrip - July 23, 2026

Executives On The Move: Three CEOs And Three CMOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Sino-Cell Biomedicine, Prolynx and Cellular Intelligence, plus Biogen gets a new CLO.
Scrip - July 23, 2026

Roche Raises Doubts About Future European Pricing Deals For Giredestrant
US approval for breast cancer drug giredestrant is expected later this year, but Roche’s leadership has raised doubts about whether it can reach satisfactory pricing deals in Europe.
Scrip - July 23, 2026

Polpharma Acquires Romania’s Biofarm For Wider Regional Growth
Polpharma’s RON1.26bn takeover of Biofarm adds Romanian manufacturing capacity, expands its CEE commercial footprint and creates a platform for portfolio growth, exports and regional integration.
HBW Insight - July 23, 2026

Where Need Leads: Why Patient Journey Should Help Shape Innovation Priorities
Innovation has traditionally been guided by scientific opportunity—but should patient burden play a greater role in determining where innovation is needed most?
Scrip - July 23, 2026

Compliance Fears Are Stalling AI In Medtech Sales, Even As Sales Reps Who Use It Outperform
An AcuityMD-sponsored survey of 150 medtech reps finds AI users 3x likelier to hit quota — but only 36% use AI, and 11% for strategic work. Compliance, training gaps and generic tools stall adoption. The device-maker question, sources argue, is now how to deploy AI, not whether.
Medtech Insight - July 23, 2026

Arcus Adds Summit, AVEO Combinations To ARC-20 Casdatifan Kidney Cancer Study
New ARC-20 cohorts add to Arcus's growing casdatifan development program, shifting attention toward how multiple combination studies could inform the drug's future clinical development in ccRCC.
Scrip - July 23, 2026

Tecvayli/Talvey Results Showcase Dual-Target Immunotherapy Strategy In Myeloma
Johnson & Johnson announced results for the combo of Tecvayli and Talvey in second-line and later disease, but it has a trispecific antibody against BCMA/GPRC5D in the works too.
Scrip - July 23, 2026

‘Regressive And Counterproductive’ – Industry Responds To Trump’s Generic Tariffs
Industry representatives from across the world have responded to Donald Trump’s recent announcement of US tariffs for generic medicines, warning that the “regressive and counterproductive” measure could hit supply, while at the same time failing to achieve its goal of incentivizing local production.
Generics Bulletin - July 23, 2026

Emcure Takes Full Control Of Gennova – With An Eye On Biosimilars
Emcure has taken full control of biopharma subsidiary Gennova Biopharmaceuticals, replacing founding CEO Sanjay Singh with Samit Mehta as it buys out a remaining 12.05% minority stake.
Generics Bulletin - July 23, 2026

Anvisa Approval Opens Latin America to Aurobindo Biosimilars
Anvisa’s approval of CuraTeQ’s Hyderabad facility strengthens Aurobindo’s ability to supply biosimilars across Brazil and Latin America while advancing its wider biologics manufacturing strategy.
Generics Bulletin - July 23, 2026

Polpharma Secures Romanian Platform For Wider Regional Growth
Polpharma’s RON1.26bn takeover of Biofarm adds Romanian manufacturing capacity, expands its CEE commercial footprint and creates a platform for portfolio growth, exports and regional integration.
Generics Bulletin - July 23, 2026

Europe Looks To Formalize Leaner Biosimilar Development
The EMA plans to overhaul its biosimilars guideline, formalizing a tailored approach that promises to eliminate routine comparative efficacy studies for well-characterized products.
Generics Bulletin - July 23, 2026

Takeda Sees Qdenga India Launch By Mid-2027, Panacea Closest Competitor
Takeda is targeting a mid-2027 India launch for Qdenga, the country's first approved dengue vaccine, at an access-oriented price that also reflects its value and benefits. The Japanese major is working towards broad availability of its first vaccine in India
Scrip - July 23, 2026

Ribo Upbeat On First-In-Class siRNA In Coronary Artery Disease
Chinese firm Ribo Life Science reports the first clinical proof-of-concept for a Factor XI-targeting siRNA, with Phase IIa data in chronic coronary artery disease showing a 92% reduction in FXI inhibition activity and no major bleeding, setting up a long-acting challenge to daily and monthly rivals.
Scrip - July 23, 2026

How Synthetic Biology Can Strengthen A Vulnerable Pharmaceutical Supply Chain
Synthetic biology offers a path to rebuild pharmaceutical supply chains dangerously dependent on China and India, using engineered microbes to consolidate and localize API production.
In Vivo - July 23, 2026

Dr Reddy’s Semaglutide Woes Ripple Through Partners, CEO Vows Comeback
With "tens of partners" globally Dr Reddy’s semaglutide supply challenges could potentially have a wider impact if the firm isn’t back in the market by November as anticipated. Partner Aspen has already flagged delays, and a Sandoz Canada supply commitment also hangs on a timely restart.
Scrip - July 23, 2026

UNPA’s Israelsen Nears Retirement Receiving University Honors, AHPA Award
Since beginning his work in natural products industry in 1980, Israelsen has helped shape its commercial, regulatory and legislative environment, most notably with a role in developing and passing the Dietary Supplement Health and Education Act of 1994.
HBW Insight - July 23, 2026

Lauder Scientist Joins Skin Ed Forum; Investment Firms Bolster Beauty Leadership With Key Hires
Estee Lauder announces one of its lead scientists has joined a prestigious education forum dedicated to skin health, while physician-dispensed Revision Skincare has appointed a chief global growth officer and investment firms tap key executives to oversee beauty brand growth.
HBW Insight - July 23, 2026